Threshold Pharmaceuticals – About the Company

Threshold Pharmaceuticals (NasdaqGM: THLD) is an oncology-focused therapeutics company. The lead molecule, TH-302, is partnered with Merck KGaA, Darmstadt, Germany, and is currently being evaluated in two Phase III trials for soft tissue sarcoma and pancreatic cancer patients. TH-302 potentially has broad applications within oncology and Threshold, Merck KGaA, and independent investigators have initiated several additional trials to expand the drug’s potential reach.